BriaCell Therapeutics (NASDAQ:BCTX) Shares Scheduled to Reverse Split on Wednesday, January 29th

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are going to reverse split before the market opens on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Trading Down 1.8 %

Shares of NASDAQ:BCTX opened at $0.38 on Tuesday. The company has a market capitalization of $16.71 million, a PE ratio of -0.42 and a beta of 1.55. BriaCell Therapeutics has a 12-month low of $0.37 and a 12-month high of $4.61. The business has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.74.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). Equities research analysts predict that BriaCell Therapeutics will post -1.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.